<DOC>
	<DOC>NCT01146340</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (40 Gy / 5 fractions / 29 days) for the treatment of low- and intermediate-risk prostate cancer.</brief_summary>
	<brief_title>Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men &gt;18 years Histologically confirmed prostate adenocarcinoma Low or lowintermediate risk prostate cancer, defined as Clinical stage T12b, Gleason Score &lt;=6, and PSA &lt;15 ng/mL, OR Clinical stage T12b, Gleason Score 7, and PSA &lt;=10 ng/mL Prior pelvic radiotherapy Anticoagulation medication (if unsafe to discontinue for gold seed insertion) Diagnosis of bleeding diathesis Presence of a hip prosthesis Pelvic girth &gt;40cm Large prostate (&gt;90cm3) on imaging Severe lower urinary tract symptoms (International Prostate Symptom Score &gt;19 or nocturia &gt;3)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Hypofractionation</keyword>
	<keyword>Low and Intermediate Risk Prostate Cancer</keyword>
</DOC>